Abstract:This review comprehensively summarizes the advances in research for fibrosis. It emphasizes organ‐specific profibrotic cell types and molecular mechanisms of fibrosis, especially in the kidney, liver, lung, and heart. The authors highlight the advanced antifibrotic small molecule drugs and cellular therapies for fibrosis. These findings have critical implications for further research and clinical translation of medicine. As the final stage of disease‐related tissue injury and repair, fibrosis is characterized by excessive accumulation of the extracellular matrix. Unrestricted accumulation of stromal cells and matrix during fibrosis impairs the structure and function of organs, ultimately leading to organ failure. The major etiology of fibrosis is an injury caused by genetic heterogeneity, trauma, virus infection, alcohol, mechanical stimuli, and drug. Persistent abnormal activation of "quiescent" fibroblasts that interact with or do not interact with the immune system via complicated signaling cascades, in which parenchymal cells are also triggered, is identified as the main mechanism involved in the initiation and progression of fibrosis. Although the mechanisms of fibrosis are still largely unknown, multiple therapeutic strategies targeting identified molecular mechanisms have greatly attenuated fibrotic lesions in clinical trials. In this review, the organ‐specific molecular mechanisms of fibrosis is systematically summarized, including cardiac fibrosis, hepatic fibrosis, renal fibrosis, and pulmonary fibrosis. Some important signaling pathways associated with fibrosis are also introduced. Finally, the current antifibrotic strategies based on therapeutic targets and clinical trials are discussed. A comprehensive interpretation of the current mechanisms and therapeutic strategies targeting fibrosis will provide the fundamental theoretical basis not only for fibrosis but also for the development of antifibrotic therapies.

Advanced 3D In Vitro Lung Fibrosis Models: Contemporary Status, Clinical Uptake, and Prospective Outlooks

Bioengineered in Vitro Tissue Model of Fibroblast Activation for Modeling Pulmonary Fibrosis

Engineered cell and tissue models of pulmonary fibrosis.

The evolution of in vitro models of lung fibrosis: promising prospects for drug discovery

Lung-on-a-Chip Systems and Other 3D Cultures

Real‐Time Measurement of Cell Mechanics as a Clinically Relevant Readout of an In Vitro Lung Fibrosis Model Established on a Bioinspired Basement Membrane

Advances in common in vitro cellular models of pulmonary fibrosis

Biomechanical Properties and Cellular Responses in Pulmonary Fibrosis

Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies

Dynamic 3D in vitro lung models: Applications of inorganic nanoparticles for model development and characterization

An alternative in vitro model considering cell-cell interactions in fiber-induced pulmonary fibrosis

A translational preclinical model of interstitial pulmonary fibrosis and pulmonary hypertension: mechanistic pathways driving disease pathophysiology

Noninvasive Imaging of Experimental Lung Fibrosis

Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies

Fibrosis: from mechanisms to medicines

3D pulmonary fibrosis model for anti-fibrotic drug discovery by inkjet-bioprinting

3D bioprinted vascularized lung cancer organoid models with underlying disease capable of more precise drug evaluation

Challenges for Clinical Drug Development in Pulmonary Fibrosis

Recent trends and applications of nanostructure-based drug delivery in alleviating pulmonary fibrosis

Cellular and Molecular Genetic Mechanisms of Lung Fibrosis Development and the Role of Vitamin D: A Review

New Therapeutic Approaches Against Pulmonary Fibrosis.